Skip to main content
main-content

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

27.03.2017 | case report | Ausgabe 3/2017

memo - Magazine of European Medical Oncology 3/2017

Disease control with brentuximab vedotin in an aged patient with primary cutaneous anaplastic large-cell lymphoma

Zeitschrift:
memo - Magazine of European Medical Oncology > Ausgabe 3/2017
Autoren:
MD Sonja Burgstaller, Josef Thaler

Summary

The patient presented here was diagnosed with multifocal primary cutaneous anaplastic large-cell lymphoma at the age of 80 years. Initially, he received chemotherapy plus prednisolone, which had to be discontinued due to toxicity. Treatment with brentuximab vedotin was then commenced, which promoted reductions in skin lesions of the patient, and was well tolerated. New lesions occurred 6 months after the start of brentuximab vedotin therapy, but were successfully controlled with irradiation. The patient experienced sustained disease control with ongoing brentuximab vedotin administration for more than 1 year. His quality of life is not compromised by this treatment in spite of his advanced age.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 3/2017

memo - Magazine of European Medical Oncology 3/2017 Zur Ausgabe